Compare Agilent Technologies Inc (A) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs UiPath Inc — how do they compare? Agilent Technologies Inc trades at $128.8 (market cap $37.04B), while UiPath Inc trades at $11.43 (market cap $6.04B). The key difference: Agilent Technologies Inc is far larger — about 6.1× UiPath Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| A | PATH | |
|---|---|---|
Market Cap | $37.04B | $6.04B |
Sector | Health | Technology |
52-Week High | $157.20 | $19.29 |
52-Week Low | $110.24 | $9.38 |
Enterprise Value | $38.59B | $4.81B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
UiPath (PATH) trades at $11.65, down 0.51% on the day, with a bullish technical signal driven by moving averages. The company shows improving fundamentals with revenue growth from $1.43B in 2025 to a projected $1.7B in 2026 and a shift to profitability. Recent news highlights expansion in agentic AI and enterprise automation, though the stock faces competitive and execution risks.
The outlook is cautiously optimistic with a consensus price target of $13.33 suggesting 14% upside. Key opportunities include strong revenue growth and margin expansion, while risks involve intense competition and the need to sustain AI-driven adoption. Analyst sentiment is mixed with 25% buy ratings amid ongoing transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
